PillRx only · Tablet · Oral
Imatinib
Imatinib Mesylate
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US2 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$1.761
Latest avg · Jul 22, 2026
-11%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volume
No Medicaid utilization on record for this drug concept yet. Quarterly volume (CMS State Drug Utilization Data) loads with the utilization ETL.
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Dr.Reddy's laboratories Limited | unknown | 8 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Feb 17, 2021RECALLRecall (Class II): Imatinib Mesylate Tablets 100mg, packaged as a) 90-count bottles (NDC 43598-344-90); and b) For Institutional Use Only …
Failed Dissolution Specifications — Recalling firm: Dr. Reddy's Laboratories, Inc. — Nationwide in the USA